KLRA · Why this verdict
Why Kailera Therapeutics (KLRA) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Kailera Therapeutics is a pre-revenue biotech down 54% from its high that has missed EPS estimates in both reported quarters; strong accumulation and institutional buying are offset by heavy losses and high volatility.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company reports zero revenue in every recent quarter and wide losses of $1.09 per share in the latest quarter, so the thesis depends entirely on pipeline progress. Revenue quarters | Quarterly losses should narrow below $0.73 per share and revenue should appear through partnership or milestone income within 12 months. | →Stable |
| CounterPre-revenue biotechs can burn cash for years, and a single trial failure can erase most of the value. | ||
Quality scores 2.5/10 with zero margins, though the current ratio component is 5 and the debt-to-equity risk component is at the best 10/10. Quality | The balance sheet should keep enough liquidity to fund operations for the next 12 months without heavy dilution. | →Stable |
| CounterZero margins and a Piotroski component of 4.4 mean cash is being consumed, and a raise at lower prices would dilute holders. | ||
EPS missed estimates in both reported quarters, by 49% in August 2026 and by 565% in May 2026, with a $3.65 loss against a $0.55 estimate. Last 4 quarters | EPS surprise should move to 0% or better in the November 2026 report and after. | →Stable |
| CounterLarge one-time charges can distort biotech quarterly EPS, and the estimates are based on thin analyst coverage. | ||
Institutions are accumulating the shares, the holder-change score is 10/10 and on-balance volume is rising, with momentum at 6.7/10. Insider breakdown | Institutional ownership should keep rising and price should hold above $11.95 over 12 months. | →Stable |
| CounterInstitutional buying after a 54% drawdown could be bottom-fishing, and there is no net insider activity to confirm it. | ||
Implied volatility is about 89% and the stock is flagged as a speculative binary biotech industry, with earnings due in 11 days. Risk breakdown | Implied volatility should compress below 70% as clinical milestones are met over 12 months. | ↑Improving |
| CounterA low put/call ratio of 0.30 suggests traders are positioned bullishly, which can reverse sharply on any clinical or earnings disappointment. | ||
The company reports zero revenue in every recent quarter and wide losses of $1.09 per share in the latest quarter, so the thesis depends entirely on pipeline progress.
→StableRevenue quarters
- Expectation
- Quarterly losses should narrow below $0.73 per share and revenue should appear through partnership or milestone income within 12 months.
CounterPre-revenue biotechs can burn cash for years, and a single trial failure can erase most of the value.
Quality scores 2.5/10 with zero margins, though the current ratio component is 5 and the debt-to-equity risk component is at the best 10/10.
→StableQuality
- Expectation
- The balance sheet should keep enough liquidity to fund operations for the next 12 months without heavy dilution.
CounterZero margins and a Piotroski component of 4.4 mean cash is being consumed, and a raise at lower prices would dilute holders.
EPS missed estimates in both reported quarters, by 49% in August 2026 and by 565% in May 2026, with a $3.65 loss against a $0.55 estimate.
→StableLast 4 quarters
- Expectation
- EPS surprise should move to 0% or better in the November 2026 report and after.
CounterLarge one-time charges can distort biotech quarterly EPS, and the estimates are based on thin analyst coverage.
Institutions are accumulating the shares, the holder-change score is 10/10 and on-balance volume is rising, with momentum at 6.7/10.
→StableInsider breakdown
- Expectation
- Institutional ownership should keep rising and price should hold above $11.95 over 12 months.
CounterInstitutional buying after a 54% drawdown could be bottom-fishing, and there is no net insider activity to confirm it.
Implied volatility is about 89% and the stock is flagged as a speculative binary biotech industry, with earnings due in 11 days.
↑ImprovingRisk breakdown
- Expectation
- Implied volatility should compress below 70% as clinical milestones are met over 12 months.
CounterA low put/call ratio of 0.30 suggests traders are positioned bullishly, which can reverse sharply on any clinical or earnings disappointment.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.7 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 5.5 |
| Volume | 1.1 |
- ▸Overbought bear rally (RSI 74)
- ▸Volume distribution (falling OBV)
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 219%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
0.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 0.1 |
| 52w position | 0.0 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.8 |
| days to cover | 4.9 |
| volatility | 0.0 |
| put call | 9.7 |
| implied vol | 0.0 |
| debt equity | 10.0 |
- ▸High IV: 147%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/2M
- ▸Earnings in 6 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.1<4.5
- EARNINGS_PROXIMITY:6d<=7d
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -52% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.1<4.5 outcome against Insider at 7.3 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 7.3, Sentiment at 6.6, and Peer rank at 5.7; the weakest are Technical at 0.4, Catalyst at 2.5, and Quality at 2.5. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pre Revenue Biotech Losses
Trip ifQuarterly EPS loss exceeds $1.50 per share from the current $1.09.
- P2Repeated Earnings Misses
Trip ifEPS surprise stays below 0% for 2 more consecutive quarters.
- P3Institutional Accumulation
Trip ifShare price falls below the $11.95 stop-loss level.
- P4Quality And Balance Sheet
Trip ifQuality score stays below 4.0 for 4 consecutive quarters from the current 2.5.
- P5High Volatility Binary Risk
Trip ifImplied volatility rises above 100% from the current 89%.